Wireless IoT leader delivers
"We delivered strong third-quarter results, with revenue up 10% sequentially, underpinned by broad-based growth across many end applications and another record quarter for medical revenue as known customer ramps continued," said
Third Quarter Financial Highlights
- Revenue was
$251 million , up 22% year-over-year - Industrial & Commercial revenue was
$141 million , up 20% year-over-year Home & Life revenue was$110 million , up 24% year-over-year- Bookings imply a healthy demand environment, while distributor inventory declined further to a multi-year low and end customer inventory was near record lows during the quarter
- Medical revenue reached a new quarterly record, increasing 48% sequentially and more than 300% year-over-year
- GAAP diluted earnings per share was
$0.26 , compared with a loss of$0.30 in the year-ago quarter - Non-GAAP diluted earnings per share was
$1.05 , up 228% over the comparable period last year
Results on a GAAP basis:
- GAAP gross margin was 60.8%
- GAAP operating expenses were
$145 million - GAAP operating income was
$8 million - GAAP diluted earnings per share was
$0.26
Results on a non-GAAP basis, excluding the impact of stock compensation, amortization of acquired intangible assets, merger-related costs, and certain other items as set forth in the below GAAP to Non-GAAP reconciliation tables were as follows:
- Non-GAAP gross margin was 61.0%
- Non-GAAP operating expenses were
$113 million - Non-GAAP operating income was
$40 million - Non-GAAP diluted earnings per share was
$1.05
Due to the announced pending acquisition of
About
Forward-Looking Statements
This press release contains forward-looking statements regarding
Note to editors:
For more information: Silicon Labs Investor Relations, investor.relations@silabs.com
| Condensed Consolidated Statements of Operations (In thousands, except per share data) (Unaudited) | |||||||
| | | | | ||||
| | Three Months Ended | | Nine Months Ended | ||||
| |
| |
| |
| |
|
| Revenues | $ 250,892 | | $ 205,999 | | $ 692,581 | | $ 576,558 |
| Cost of revenues | 98,314 | | 86,980 | | 272,331 | | 251,653 |
| Gross profit | 152,578 | | 119,019 | | 420,250 | | 324,905 |
| Operating expenses: | | | | | | | |
| Research and development | 93,174 | | 87,685 | | 276,784 | | 263,725 |
| Selling, general and administrative | 51,453 | | 43,676 | | 163,263 | | 128,469 |
| Operating expenses | 144,627 | | 131,361 | | 440,047 | | 392,194 |
| Operating income (loss) | 7,951 | | (12,342) | | (19,797) | | (67,289) |
| Other income (expense): | | | | | | | |
| Interest income and other, net | 3,185 | | 3,046 | | 9,300 | | 10,672 |
| Interest expense | (226) | | (226) | | (709) | | (761) |
| Income (loss) before income taxes | 10,910 | | (9,522) | | (11,206) | | (57,378) |
| Provision for income taxes | 2,059 | | 414 | | 6,432 | | 4,845 |
| Net income (loss) | $ 8,851 | | $ (9,936) | | $ (17,638) | | $ (62,223) |
| | | | | | | | |
| Earnings (loss) per share: | | | | | | | |
| Basic | $ 0.27 | | $ (0.30) | | $ (0.53) | | $ (1.91) |
| Diluted | $ 0.26 | | $ (0.30) | | $ (0.53) | | $ (1.91) |
| | | | | | | | |
| Weighted-average common shares outstanding: | | | | | | | |
| Basic | 33,376 | | 32,835 | | 33,182 | | 32,656 |
| Diluted | 33,752 | | 32,835 | | 33,182 | | 32,656 |
Non-GAAP Financial Measurements
In addition to the GAAP results provided throughout this document,
The non-GAAP financial measurements do not replace the presentation of
| Unaudited Reconciliation of GAAP to Non-GAAP Financial Measures (In thousands, except per share data) | ||||||||||||||
| | | | ||||||||||||
| | | Three Months Ended | ||||||||||||
| Non-GAAP Income Statement Items | | GAAP Measure | | GAAP Percent of Revenue | | Stock Compensation Expense | | Intangible Amortization | | Merger- | | Non- Measure | | Non-GAAP Percent of Revenue |
| Revenues | | $ 250,892 | | | | | | | | | | | | |
| | | | | | | | | | | | | | | |
| Gross profit | | 152,578 | | 60.8 % | | $ 459 | | $ — | | $ — | | | | 61.0 % |
| | | | | | | | | | | | | | | |
| Research and development | | 93,174 | | 37.1 % | | 11,996 | | 2,295 | | 3,623 | | 75,260 | | 30.0 % |
| | | | | | | | | | | | | | | |
| Selling, general and administrative | | 51,453 | | 20.5 % | | 10,594 | | — | | 3,281 | | 37,578 | | 15.0 % |
| | | | | | | | | | | | | | | |
| Operating expenses | | 144,627 | | 57.6 % | | 22,590 | | 2,295 | | 6,904 | | 112,838 | | 45.0 % |
| | | | | | | | | | | | | | | |
| Operating income | | 7,951 | | 3.2 % | | 23,049 | | 2,295 | | 6,904 | | 40,199 | | 16.0 % |
| | | Three Months Ended | ||||||||||
| Non-GAAP Earnings Per Share | | GAAP Measure | | Stock Compensation Expense* | | Intangible Asset Amortization* | | Merger- | | Income Tax Adjustments** | | Non- GAAP Measure |
| Net income (loss) | | $ 8,851 | | $ 23,049 | | $ 2,295 | | $ 6,904 | | $ (5,710) | | $ 35,389 |
| | | | | | | | | | | | | |
| | | | | | | | ||||||
| Diluted shares outstanding | | 33,752 | | | | 33,752 | ||||||
| | | | | | | | | | | | | |
| Diluted earnings per share | | $ 0.26 | | | | | | | | | | $ 1.05 |
| * Represents pre-tax amounts |
| ** Represents the application of an 18% non-GAAP tax rate |
| Condensed Consolidated Balance Sheets (In thousands, except per share data) (Unaudited) | |||
| | | | |
| |
| |
|
| Assets | | | |
| Current assets: | | | |
| Cash and cash equivalents | $ 423,013 | | $ 364,222 |
| Short-term investments | 16,828 | | 79,400 |
| Accounts receivable, net | 79,966 | | 64,513 |
| Inventories | 133,391 | | 95,566 |
| Prepaid expenses and other current assets | 71,421 | | 70,316 |
| Total current assets | 724,619 | | 674,017 |
| Property and equipment, net | 131,687 | | 128,643 |
| | 376,389 | | 376,389 |
| Other intangible assets, net | 16,246 | | 23,130 |
| Other assets, net | 87,213 | | 67,138 |
| Total assets | $ 1,336,154 | | $ 1,269,317 |
| Liabilities and Stockholders' Equity | | | |
| Current liabilities: | | | |
| Accounts payable | $ 68,860 | | $ 50,717 |
| Deferred revenue and returns liability | 9,804 | | 5,359 |
| Other current liabilities | 78,841 | | 87,711 |
| Total current liabilities | 157,505 | | 143,787 |
| Other non-current liabilities | 53,267 | | 31,112 |
| Total liabilities | 210,772 | | 174,899 |
| Commitments and contingencies | | | |
| Stockholders' equity: | | | |
| Preferred stock – | — | | — |
| Common stock – | 3 | | 3 |
| Additional paid-in capital | 206,203 | | 157,402 |
| Retained earnings | 919,176 | | 936,814 |
| Accumulated other comprehensive income | — | | 199 |
| Total stockholders' equity | 1,125,382 | | 1,094,418 |
| Total liabilities and stockholders' equity | $ 1,336,154 | | $ 1,269,317 |
| Condensed Consolidated Statements of Cash Flows (In thousands) (Unaudited) | |||
| | | ||
| | Nine Months Ended | ||
| |
| |
|
| Operating Activities | | | |
| Net loss | $ (17,638) | | $ (62,223) |
| Adjustments to reconcile net loss to net cash provided by operating activities: | | | |
| Depreciation of property and equipment | 18,154 | | 18,769 |
| Amortization of other intangible assets | 6,884 | | 11,074 |
| Stock-based compensation expense | 69,754 | | 59,645 |
| Deferred income taxes | 2,164 | | 2,026 |
| Changes in operating assets and liabilities: | | | |
| Accounts receivable | (15,453) | | (12,829) |
| Inventories | (37,828) | | 23,316 |
| Prepaid expenses and other assets | (35,213) | | 9,080 |
| Accounts payable | 18,373 | | 11,141 |
| Other current liabilities and income taxes | 3,271 | | 29,901 |
| Deferred revenue and returns liability | 4,445 | | 5,374 |
| Other non-current liabilities | 20,285 | | (7,916) |
| Net cash provided by operating activities | 37,198 | | 87,358 |
| | | | |
| Investing Activities | | | |
| Purchases of marketable securities | — | | (34,790) |
| Sales of marketable securities | — | | 15,332 |
| Maturities of marketable securities | 62,309 | | 22,598 |
| Purchases of property and equipment | (28,472) | | (19,942) |
| Proceeds from capital-related government incentives | 8,705 | | — |
| Purchase of other investment | — | | (4,000) |
| Net cash provided by (used in) investing activities | 42,542 | | (20,802) |
| | | | |
| Financing Activities | | | |
| Payment of taxes withheld for vested stock awards | (28,710) | | (14,907) |
| Proceeds from the issuance of common stock | 7,761 | | 8,147 |
| Net cash used in financing activities | (20,949) | | (6,760) |
| | | | |
| Increase in cash and cash equivalents | 58,791 | | 59,796 |
| Cash and cash equivalents at beginning of period | 364,222 | | 281,607 |
| Cash and cash equivalents at end of period | $ 423,013 | | $ 341,403 |
View original content to download multimedia:https://www.prnewswire.com/news-releases/silicon-labs-reports-third-quarter-2026-results-302935539.html
SOURCE